ArticleNeurosurgery2019
Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study.
Article in Neurosurgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Radiation therapy in functioning and no functioning pituitary neuroendocrine tumor: systematic review of the recent literature after 2011.Frontiers in endocrinology · 2024Pooled it
- Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes.Journal of neuro-oncology · 2020Pooled it
- Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027Review
- Article
- Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.Pituitary · 2026Review
- LINAC-based Stereotactic Radiotherapy for Acromegaly: A Single-center Retrospective Cohort.Journal of neurological surgery. Part B, Skull base · 2026Article
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- Acromegaly in Northeastern Romania: Clinical Characteristics, Therapeutic Management, and Disease Control in a Tertiary Center.Life (Basel, Switzerland) · 2026Article
- Current treatment landscape of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- The Journey of Acromegaly Towards Treatment: A Single-Center Study.Journal of personalized medicine · 2026Article
- Clinical, hormonal, and treatment outcomes in 247 patients with acromegaly: a single tertiary center experience.Turkish journal of medical sciences · 2026Article
- Radiotherapeutic Strategies and Advances in the Management of Pituitary Adenomas.Neuroendocrinology · 2026Review
- Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy.Acta neurochirurgica · 2025Article
- Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors.Neuro-oncology advances · 2025Article
- The Long-Term Effects of Postoperative Radiotherapy in Acromegaly: Results From a Single-Center Acromegaly Registry in Iran.International journal of endocrinology · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Predictors of biochemical remission after transsphenoidal surgery in a large cohort of acromegaly patients.Pituitary · 2024Article
- Contemporary radiotherapy and radiosurgery techniques for refractory pituitary adenomas.Pituitary · 2023Article
- Prospective intraoperative and histologic evaluation of cavernous sinus medial wall invasion by pituitary adenomas and its implications for acromegaly remission outcomes.Scientific reports · 2022Article
- Modern Linear Accelerator-Based Radiotherapy Is Safe and Effective in the Treatment of Secretory and Nonsecretory Pituitary Adenomas.World neurosurgery · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Funding
Abstract
backgroundStereotactic radiosurgery (SRS) is a treatment option for persistent or recurrent acromegaly secondary to a growth hormone secreting pituitary adenoma, but its efficacy is inadequately defined.
objectiveTo assess, in a multicenter, retrospective cohort study, the outcomes of SRS for acromegaly and determine predictors.
methodsWe pooled and analyzed data from 10 participating institutions of the International Gamma Knife Research Foundation for patients with acromegaly who underwent SRS with endocrine follow-up of ≥6 mo.
resultsThe study cohort comprised 371 patients with a mean endocrine follow-up of 79 mo. IGF-1 lowering medications were held in 56% of patients who were on pre-SRS medical therapy. The mean SRS treatment volume and margin dose were 3.0 cm3 and 24.2 Gy, respectively. The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively. The mean time to durable remission after SRS was 38 mo. Biochemical relapse after initial remission occurred in 9%, with a mean time to recurrence of 17 mo. Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission (P = .01). Adverse radiation effects included the development of ≥1 new endocrinopathy in 26% and ≥1 cranial neuropathy in 4%.
conclusionSRS is a definitive treatment option for patients with persistent or recurrent acromegaly after surgical resection. There appears to be a statistical association between the cessation of IGF-1 lowering medications prior to SRS and durable remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.